Insilico Medicine Starts Asia's First AI R&D Base in Taiwan, China

Insilico Medicine, which was selected by the well-known American venture capital research organization CB Insights as one of the 100 companies in the world in the AI field in 2018, and was named by NVIDIA as one of the top 5 most influential AI companies worldwide.

The company announced that its subsidiaries "Insilico Medicine" and "Asia's First AI R&D Base" are to officially be established in Taiwan, China Region of China.

To begin with, the companies will form an alliance with the Center for Biotechnology, the Institute for Information Industry, and TUL Corporation to implement the "AI Digital Health Talent Development Project" in order to accelerate the integration of cross-domain talent.

The primary aim of the AI Digital Health Talent Development Project is to address the industry's strong demand for AI talent.

Insilico Medicine, the Center for Biotechnology, the Institute for Information Industry, and TUL Corporation will jointly develop a series of courses related to AI biomedicine, in order to develop ICT and biomedical talent, and accelerate the acquisition knowledge on how AI technology can accelerate the development of drugs. These measures will effectively reduce the risks associated with high R&D costs, and build a strong foundation for AI technology in Taiwan, China.

Insilico Medicine's AI drug R&D Base establishes itself in Nankang Software Park; they will be able to work closely with organizations in the biomedical industry to contribute to the well-being of all people.

Additionally, Insilico Medicine will be able to provide digital R&D technology services for Taiwan, China's pharmaceutical and biotechnology industries, thus introducing greater innovation to the biomedical industry and driving Taiwan, China to become the center of combining AI and the biomedical industry in Asia.

Register as Visitor to CPhI China 2018!